Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.86 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.86 |
| ▸ | DRD2 | P14416 | 6/20 | 0.86 |
| ▸ | LMNA | P02545 | 5/20 | 0.86 |
| ▸ | TP53 | P04637 | 5/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.86 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.86 |
| ▸ | HTR1A | P08908 | 5/20 | 0.86 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.86 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.86 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.86 |
| ▸ | HTR2A | P28223 | 5/20 | 0.86 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.86 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.86 |
| ▸ | HRH1 | P35367 | 5/20 | 0.86 |
| ▸ | DRD3 | P35462 | 5/20 | 0.86 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.86 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.86 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prochlorperazine SCHEMBL18429 | 0.93 | DRD2 (1.00) | MAPTMAPK1DRD2LMNATP53 | |
| Prochlorperazine SCHEMBL29358207 | 0.93 | DRD2 (1.00) | MAPTMAPK1DRD2LMNATP53 | |
| Prochlorperazine SCHEMBL14126977 | 0.93 | DRD2 (1.00) | MAPTMAPK1DRD2LMNATP53 | |
| Prochlorperazine SCHEMBL29369439 | 0.93 | DRD2 (1.00) | MAPTMAPK1DRD2LMNATP53 | |
| Prochlorperazine SCHEMBL133595 | 0.92 | DRD2 (0.98) | MAPTMAPK1DRD2LMNATP53 | |
| Prochlorperazine SCHEMBL1041250 | 0.92 | DRD2 (0.98) | MAPTMAPK1DRD2LMNATP53 | |
| Prochlorperazine SCHEMBL2506559 | 0.92 | DRD2 (0.98) | MAPTMAPK1DRD2LMNATP53 | |
| Perazine SCHEMBL29390464 | 0.88 | KDM1A (1.00) | MAPTMAPK1DRD2LMNATP53 | |
| Perazine SCHEMBL147165 | 0.88 | KDM1A (1.00) | MAPTMAPK1DRD2LMNATP53 | |
| Perphenazine SCHEMBL5307579 | 0.88 | MAPT (0.91) | MAPTMAPK1DRD2LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA, LLC | 2017-10-12 | — | — | US | disclosed |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA, LLC | 2017-10-12 | — | — | US | disclosed |
| US-9616035-B2 | Pharmaceutical for oral delivery comprising MGBG and methods of treating disease | PATHOLOGICA, LLC (US) | 2017-04-11 | — | — | US | disclosed |
| US-9616035-B2 | Pharmaceutical for oral delivery comprising MGBG and methods of treating disease | PATHOLOGICA, LLC (US) | 2017-04-11 | — | — | US | disclosed |
| US-20140051765-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051765-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-8383617-B2 | Treatment of protein aggregation diseases | PAD PHARMA LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| US-8383617-B2 | Treatment of protein aggregation diseases | PAD PHARMA LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| US-20100035859-A1 | TREATMENT OF PROTEIN AGGREGATION DISEASES | PAD PHARMA LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20100035859-A1 | TREATMENT OF PROTEIN AGGREGATION DISEASES | PAD PHARMA LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| WO-2008092898-A1 | TREATMENT OF PROTEIN AGGREGATION DISEASES | PAD PHARMA LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051765-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | MAPT 3214/4885MAPK1 3478/4885DRD2 4803/4885 |
| US-20100035859-A1 | TREATMENT OF PROTEIN AGGREGATION DISEASES | PRNP, TTR, HTT | MAPT 16/4885MAPK1 3403/4885DRD2 4749/4885 |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | MAPT 3214/4885MAPK1 3478/4885DRD2 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.